Abstract
Refractory soft tissue sarcomas carry a poor prognosis and limited treatment options require the use of new chemotherapeutic agents. We report the case of an eight year old boy with non metastatic alveolar rhabdomyosarcoma of the right forearm (Group 3, Stage III). After treatment failure of several chemotherapeutic regimens and progression of his disease, Trabectedin was administered at 1.3 mg/m2/dose intravenously over 24 hours for two cycles. The patients quality of life improved as noted by a significant decrease in opiate requirements and ability to tolerate oral intake. The drug was well tolerated with the exception of transient neutropenia.
Keywords: ET-743, pediatric solid tumors, refractory sarcoma, Trabectedin, neutropenia, diagnosis, chemotherapeutic agents, palliative tumor, osteosarcoma, dose limiting toxicity
Current Drug Therapy
Title: Palliative Tumor Control by Trabectedin in Pediatric Advanced Sarcoma
Volume: 6 Issue: 2
Author(s): Roula A. Farah, Soumana C. Nasser, Racha A. Sabbagh, Pele B. Dina and Toufic A. Eid
Affiliation:
Keywords: ET-743, pediatric solid tumors, refractory sarcoma, Trabectedin, neutropenia, diagnosis, chemotherapeutic agents, palliative tumor, osteosarcoma, dose limiting toxicity
Abstract: Refractory soft tissue sarcomas carry a poor prognosis and limited treatment options require the use of new chemotherapeutic agents. We report the case of an eight year old boy with non metastatic alveolar rhabdomyosarcoma of the right forearm (Group 3, Stage III). After treatment failure of several chemotherapeutic regimens and progression of his disease, Trabectedin was administered at 1.3 mg/m2/dose intravenously over 24 hours for two cycles. The patients quality of life improved as noted by a significant decrease in opiate requirements and ability to tolerate oral intake. The drug was well tolerated with the exception of transient neutropenia.
Export Options
About this article
Cite this article as:
A. Farah Roula, C. Nasser Soumana, A. Sabbagh Racha, B. Dina Pele and A. Eid Toufic, Palliative Tumor Control by Trabectedin in Pediatric Advanced Sarcoma, Current Drug Therapy 2011; 6 (2) . https://dx.doi.org/10.2174/157488511795304912
DOI https://dx.doi.org/10.2174/157488511795304912 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Effect of Chemotherapy/Radiotherapy on Cancerous Pattern Recognition by NK Cells
Current Medicinal Chemistry Target Driven Preclinical Screening for New Antimitotic Chemotherapy Agents
Current Topics in Medicinal Chemistry Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
Current Medicinal Chemistry Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Current Pharmaceutical Design Understanding FOXO, New Views on Old Transcription Factors
Current Cancer Drug Targets DNA Repair Proteins as Molecular Targets for Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Docking and QSAR Studies of Aryl-valproic Acid Derivatives to Identify Antiproliferative Agents Targeting the HDAC8
Anti-Cancer Agents in Medicinal Chemistry Fungal Proteins with Antiproliferative and Anticancer Activities
Protein & Peptide Letters Chest Pain in Children
Current Pediatric Reviews BUB1B Promotes Proliferation of Prostate Cancer via Transcriptional Regulation of MELK
Anti-Cancer Agents in Medicinal Chemistry The Antitumor Effects of Britanin on Hepatocellular Carcinoma Cells and its Real-Time Evaluation by In Vivo Bioluminescence Imaging
Anti-Cancer Agents in Medicinal Chemistry Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry Genetics of Bladder Malignant Tumors in Childhood
Current Genomics Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor
Current Respiratory Medicine Reviews Metallothioneins and Cancer
Current Protein & Peptide Science Zebrafish Model in Drug Safety Assessment
Current Pharmaceutical Design Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design
Current Drug Metabolism